Physician profile
James Richards
NPI 1154359370
$1,195.01
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $240 · 2021: $27.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.64 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $96.36 | 2019-2020 | |
| Pfizer INC. | $96.24 | 2019-2020 | |
| Exeltis, USA INC. | $77.12 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $69.98 | 2019-2020 | |
| Avion Pharmaceuticals | $65.47 | 2019-2020 | |
| Therapeuticsmd, INC. | $60.35 | 2019 | |
| Merck Sharp & Dohme LLC | $43.28 | 2019-2020 | |
| Lupin INC. | $40.84 | 2019 | |
| Amgen INC. | $40.71 | 2019-2020 | |
| Millicent US INC | $38.71 | 2020 | |
| Daiichi Sankyo INC. | $37.58 | 2019 | |
| Kedrion Biopharma INC. | $34.88 | 2019 | |
| Davol INC. | $29.36 | 2020 | |
| Hologic Sales and Service, LLC | $26.83 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $20.95 | 2019 | |
| Duchesnay USA Incorporated | $15.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.53 | 2020 | |
| Acessa Health INC. | $12.26 | 2019 | |
| Allergan, INC. | $11.23 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.